@misc{10481/66053,
year = {2020},
url = {http://hdl.handle.net/10481/66053},
abstract = {Objectives: To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a
day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg orally daily
on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in
clearing the coronavirus (COVID-19) nucleic acid from throat and nasal swab and in bringing about clinical
improvement on day 7 of follow-up (primary outcomes).},
organization = {University of Health Sciences (UHS) Lahore, Punjab, Pakistan},
publisher = {BMC},
keywords = {COVID-19},
keywords = {Randomised controlled trial},
keywords = {Protocol},
keywords = {SARS-CoV-2},
keywords = {Hydroxychloroquine},
keywords = {Azithromycin},
keywords = {Oseltamivir},
keywords = {Multi-center},
keywords = {Adaptive},
keywords = {Randomization},
title = {Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial},
doi = {10.1186/s13063-020-04616-4},
author = {Akram, Javed and Saeed Khan, Khalid},
}